1998
DOI: 10.1016/s0015-0282(97)00524-4
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Pharmacology of Recombinant Human Follicle-Stimulating Hormone (FSH). I. Comparative Pharmacokinetics with Urinary Human FSH

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

3
18
3
2

Year Published

2004
2004
2016
2016

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 34 publications
(26 citation statements)
references
References 20 publications
3
18
3
2
Order By: Relevance
“…Its amino acid sequence is identical to that of hFSH (Prevost, 1998). The in vitro and in vivo biological activities of rhFSH and hFSH are indistinguishable (Mannaerts et al, 1991, and present report) and their pharmacokinetic characteristics are similar (le Cotonnec et al, 1994). As a direct marker for the receptor we used FSHR225 which has two favorable features: it binds to the extracellular domain of the receptor and does not interfere with the receptor function (i.e., hormone binding and stimulation of adenylate cyclase) (Vannier et al, 1996, and present report).…”
Section: Discussionsupporting
confidence: 55%
“…Its amino acid sequence is identical to that of hFSH (Prevost, 1998). The in vitro and in vivo biological activities of rhFSH and hFSH are indistinguishable (Mannaerts et al, 1991, and present report) and their pharmacokinetic characteristics are similar (le Cotonnec et al, 1994). As a direct marker for the receptor we used FSHR225 which has two favorable features: it binds to the extracellular domain of the receptor and does not interfere with the receptor function (i.e., hormone binding and stimulation of adenylate cyclase) (Vannier et al, 1996, and present report).…”
Section: Discussionsupporting
confidence: 55%
“…Most previous studies on the pharmacokinetics of FSH using intravenous or subcutaneous injections reported data for up to 120-144 hours because the serum FSH dropped to the baseline level during those time ranges (3,14,15). The t 1/2 of rhFSH for abdominal mesotherapy administration in the present study is 2.5 times (102 vs. 46 hours) that of conventional subcutaneous injection at 120 hours (10).…”
mentioning
confidence: 43%
“…Since we measured FSH approxi¬ mately 24 h after the latest FSH injection, the levels found here are likely to deviate from the maximal levels of FSH reached within the first few hours after the injection. Pharmacokinetic analysis has shown that after a single s.c. injection of FSH, the maximal serum level was reached approximately 16 h after the injection, with a terminal half-life of 30 h. After repeated daily s.c. injections of recombinant human FSH, a steady state was reached after approximately four days (8,9). In our study, therefore, only FSH levels measured >4 days after dose adjustment are included.…”
Section: Discussionmentioning
confidence: 99%